News

The deal advances Biogen’s immunology strategy, focussing on established immune mechanisms that may address inflammatory disorders with considerable unmet need. Biogen’s early-stage immunology pipeline is bolstered by the

The focus of this partnership is to create a new vaccine utilising a non-replicating highly attenuated vaccinia virus, designed to enhance safety and reduce the risk of emergence

This comes just two weeks after its US Food and Drug Administration (FDA) approval. The approval is based on results from FIBRONEER-IPF, a Phase III trial in IPF

In preclinical and Phase I studies in healthy participants, PORT-77 demonstrated a substantial reduction of plasma protoporphyrin IX (PPIX) through rapid ABCG2 inhibition. This outcome has the potential

Under this agreement, McKesson will act as an authorised distributor for the immunotherapy that has received approval from the US Food and Drug Administration (FDA) to treat adults

This partnership will utilise Tempus’ de-identified multimodal database to guide the design of clinical trials. Under the multi-year agreement, Whitehawk will utilise Tempus’ real-world dataset to focus on

The inhaler administers three active ingredients through a single device, known as single inhaler triple therapy (SITT), which has already received approval in nearly 50 countries. It combines

The collaboration aims to clarify the underlying mechanism of action of iQ-007. The results will assist in stratifying and identifying patients who may benefit from this astrocyte-targeted therapy,

The FDA has also approved BeOne’s application to participate in Project Orbis, an initiative that offers a framework for concurrent submission and oncology products review among collaborating health